Integras Partners LLC Purchases New Holdings in Colgate-Palmolive (NYSE:CL)

Integras Partners LLC purchased a new stake in Colgate-Palmolive (NYSE:CL) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 28,559 shares of the company’s stock, valued at approximately $2,596,000. Colgate-Palmolive makes up approximately 2.2% of Integras Partners LLC’s holdings, making the stock its 19th biggest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC purchased a new position in Colgate-Palmolive in the 4th quarter worth approximately $26,000. Centricity Wealth Management LLC purchased a new position in Colgate-Palmolive in the 4th quarter worth approximately $27,000. Union Bancaire Privee UBP SA purchased a new position in Colgate-Palmolive in the 4th quarter worth approximately $32,000. Briaud Financial Planning Inc purchased a new position in Colgate-Palmolive in the 4th quarter worth approximately $32,000. Finally, Wintrust Investments LLC purchased a new position in Colgate-Palmolive in the 4th quarter worth approximately $33,000. 80.41% of the stock is owned by hedge funds and other institutional investors.

Colgate-Palmolive Stock Performance

Shares of CL stock opened at $90.41 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.92 and a debt-to-equity ratio of 13.40. Colgate-Palmolive has a 52 week low of $85.32 and a 52 week high of $109.30. The stock has a market capitalization of $73.37 billion, a PE ratio of 25.69, a P/E/G ratio of 4.20 and a beta of 0.40. The firm has a 50 day moving average of $89.03 and a two-hundred day moving average of $94.93.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings results on Friday, January 31st. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.90 by $0.01. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. During the same period in the previous year, the firm posted $0.87 earnings per share. On average, research analysts predict that Colgate-Palmolive will post 3.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CL has been the topic of a number of research reports. UBS Group decreased their target price on shares of Colgate-Palmolive from $104.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 3rd. TD Cowen cut their price target on shares of Colgate-Palmolive from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Piper Sandler cut their price target on shares of Colgate-Palmolive from $121.00 to $112.00 and set an “overweight” rating for the company in a report on Monday, January 6th. Barclays cut their price target on shares of Colgate-Palmolive from $96.00 to $83.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Finally, StockNews.com upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $101.61.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.